Biotech News

Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors

Aptevo Therapeutics (APVO)Aptevo Therapeutics2026-06-30 12:05 ESTSEC filing

SEATTLE, WA / ACCESS Newswire / June 30, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced it has been awarded a $1.5 million

Open original release

Related news

APVOAptevo Therapeutics2026-06-25 13:46 EST

Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer

APVOAptevo Therapeutics2026-06-25 13:46 EST

Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing

APVOAptevo Therapeutics2026-06-25 13:46 EST

Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection

APVOAptevo Therapeutics2026-06-25 13:46 EST

Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update

APVOAptevo Therapeutics2026-06-25 13:46 EST

Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors

APVOAptevo Therapeutics2026-06-25 13:46 EST

Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025

APVOAptevo Therapeutics2026-06-25 13:46 EST

Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split

APVOAptevo Therapeutics2026-06-25 13:46 EST

Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality

APVOAptevo Therapeutics2026-06-25 13:46 EST

Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth

APVOAptevo Therapeutics2026-06-25 13:46 EST

Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%

View all latest news

Aptevo Therapeutics

Aptevo Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

APVOZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

APVOZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

APVOBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

APVOGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

APVOMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close: 4.15 USD
Market cap: 4.91M USD
Exchange: NASDAQ
Sector: Biotechnology
Location: United States